Elizabeth Griffiths, MD
Elizabeth Griffiths, MD
Elizabeth Griffiths, MD, joined Roswell Park’s Leukemia Service in the Department of Medicine in March 2010. Dr. Griffiths treats patients with blood disorders, specifically acute myeloid and lymphoid leukemias as well as bone marrow failure syndromes such as aplastic anemia and myelodysplastic syndrome. The program in myelodysplasia at RPCI is recognized by the MDS Foundation as an MDS Center of Excellence. She is a Clinical Assistant Professor at the State University of New York (SUNY) at Buffalo and is a faculty member of the Roswell Park Cancer Institute-SUNY Buffalo graduate training programs in the departments of Pharmacology and Therapeutics as well as Immunology.
She joined RPCI following completion of a five-year medical oncology and hematology fellowship at the Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins Hospital in Baltimore, MD. She had previously completed her internal medicine residency, also at Johns Hopkins, in 2005. Dr. Griffiths graduated with honors in 2002, earning her degree as Doctor of Medicine with Distinction from the University of North Carolina School of Medicine, Chapel Hill.
Dr. Griffiths is board certified in hematology, oncology and internal medicine and is licensed in both New York and Maryland. Dr. Griffith’s is a member of multiple professional organizations, including the American Society of Hematology, the American Association for Cancer Research, and the American Society of Oncology.
Her research focuses on the mechanism of action of hypomethylating drugs (HMAs), specifically the contribution of the immune system to these responses. Her research examines the potential contribution of re-expressed Cancer-Germline antigens to the induction of anti-leukemic immune responses, as well as the direct impact on T-cell subsets in patients with myeloid malignancy following exposure to HMAs. She has authored or co-authored over 20 peer-reviewed publications.
- Griffiths EA, Gore SD. Epigenetic therapies in MDS and AML. Advances in experimental medicine and biology 2013; 754 :253-283
- Vigil CE, Griffiths EA, Wang ES, Wetzler M. Interpretation of cytogenetic and molecular results in patients treated for CML. Blood reviews 2011; 253:139-146
- Griffiths EA, Herman JG, Ye Y, Mohammad HP, Smith BD, Karp JE, McDevitt MA, Hooker C, Gore SD, Carraway HE. Acute myeloid leukemia is characterized by Wnt pathway inhibitor promoter hypermethylation. Leukemia and lymphoma 2010; 519:1711-1719
- Bailey VJ , Keeley BP , Razavi CR , Griffiths E , Carraway HE , Wang T-H. DNA methylation detection using MS-qFRET, a quantum dot-based nanoassay. Methods (San Diego, Calif.) 2010; 523:237-241
- Griffiths EA , Gore SD , Hooker CM , Mohammad HP , McDevitt MA , Smith BD , Karp JE , Herman JG , Carraway HE. Epigenetic differences in cytogenetically normal versus abnormal acute myeloid leukemia. Epigenetics 2010; 57:590-600